BUY Glenmark Pharmaceuticals — Prakash Gaba, 24 Aug 2026

byPrakash GabaHorizon: NA (inferred Swing (≤2wk))24 Aug 2026via CNBC Awaaz.

Entry₹2,371.7Inferred

Target₹2,400

Stop loss₹2,355-0.70% risk

Exit₹2,40025 Aug 2026, 9:15 am

Target hit+1.19%0.00%upside left

Follow Prakash Gaba for new calls(28% target hit, 184 closed calls)Get alerts Watch GLENMARK for new buy/sell callsGet alerts See 1 active Swing call on GLENMARK

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 25 Aug 2026

4 supporting1 neutral1 opposing

Supports the BUY call (4)

3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·24 Aug · today

Glenmark Pharmaceuticals Inc., USA has launched a new Calcium Gluconate Injection product in various strengths and vial sizes.

BSE · Company Update·21 Aug · 4d ago

Glenmark Pharmaceuticals has received approval from the U.S. FDA for its Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray.

BSE · Company Update·20 Aug · 5d ago

3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·20 Aug · 5d ago

Neutral / worth noting (1)

Glenmark USA has agreed to a settlement of $15.28 million to resolve antitrust and consumer protection lawsuits related to price-fixing allegations. The company denies all allegations and states the s

BSE · Company Update·11 Aug · 2w ago

Weighs against the BUY call (1)

Glenmark Pharma US arm agrees to $15.28 million settlement with Humana over antitrust lawsuits

NewsCnbc-Tv18·12 Aug · 2w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.